These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 29737220)

  • 1. Emerging reverse transcriptase inhibitors for HIV-1 infection.
    Rai MA; Pannek S; Fichtenbaum CJ
    Expert Opin Emerg Drugs; 2018 Jun; 23(2):149-157. PubMed ID: 29737220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current and emerging non-nucleoside reverse transcriptase inhibitors (NNRTIs) for HIV-1 treatment.
    Wang Y; De Clercq E; Li G
    Expert Opin Drug Metab Toxicol; 2019 Oct; 15(10):813-829. PubMed ID: 31556749
    [No Abstract]   [Full Text] [Related]  

  • 3. Current insights and molecular docking studies of HIV-1 reverse transcriptase inhibitors.
    Singh AK; Kumar A; Arora S; Kumar R; Verma A; Khalilullah H; Jaremko M; Emwas AH; Kumar P
    Chem Biol Drug Des; 2024 Jan; 103(1):e14372. PubMed ID: 37817296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals.
    Mbuagbaw L; Mursleen S; Irlam JH; Spaulding AB; Rutherford GW; Siegfried N
    Cochrane Database Syst Rev; 2016 Dec; 12(12):CD004246. PubMed ID: 27943261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human immunodeficiency virus mutagenesis during antiviral therapy: impact of drug-resistant reverse transcriptase and nucleoside and nonnucleoside reverse transcriptase inhibitors on human immunodeficiency virus type 1 mutation frequencies.
    Chen R; Yokoyama M; Sato H; Reilly C; Mansky LM
    J Virol; 2005 Sep; 79(18):12045-57. PubMed ID: 16140780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An introduction to nucleoside and nucleotide analogues.
    Squires KE
    Antivir Ther; 2001; 6 Suppl 3():1-14. PubMed ID: 11678469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current status of the non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1.
    Balzarini J
    Curr Top Med Chem; 2004; 4(9):921-44. PubMed ID: 15134549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elsulfavirine: First Global Approval.
    Al-Salama ZT
    Drugs; 2017 Oct; 77(16):1811-1816. PubMed ID: 28940154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of Structure-based Methods to Analyze Resistance Mutations for Chemically Diverse Non-Nucleoside Reverse Transcriptase Inhibitors.
    Tabassum T; Azeem SM; Muwonge AN; Frey KM
    Curr HIV Res; 2020; 18(4):283-291. PubMed ID: 32493197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigational reverse transcriptase inhibitors for the treatment of HIV.
    Cory TJ; Midde NM; Rao P; Kumar S
    Expert Opin Investig Drugs; 2015; 24(9):1219-28. PubMed ID: 26088266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Pharmacodynamics, Pharmacokinetics, and Drug Interaction Profile of Doravirine.
    Boyle A; Moss CE; Marzolini C; Khoo S
    Clin Pharmacokinet; 2019 Dec; 58(12):1553-1565. PubMed ID: 31388941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of dolutegravir in combination with Nucleoside Reverse Transcriptase Inhibitors (NRTIs) on people living with HIV who have pre-existing NRTI mutations.
    Sörstedt E; Carlander C; Flamholc L; Hejdeman B; Svedhem V; Sönnerborg A; Gisslén M; Yilmaz A
    Int J Antimicrob Agents; 2018 May; 51(5):733-738. PubMed ID: 29371105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV-1 genotype after interruption of non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy and virological response after resumption of the same regimen.
    Sungkanuparph S; Kiertiburanakul S; Apisarnthanarak A; Malathum K; Sathapatayavongs B
    Int J STD AIDS; 2007 Dec; 18(12):832-4. PubMed ID: 18073016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1: clinical, phenotypic and genotypic correlates.
    Whitcomb JM; Huang W; Limoli K; Paxinos E; Wrin T; Skowron G; Deeks SG; Bates M; Hellmann NS; Petropoulos CJ
    AIDS; 2002 Oct; 16(15):F41-7. PubMed ID: 12370521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of nucleoside/nucleotide reverse transcriptase inhibitors for the treatment and prevention of HIV infection.
    Wonganan P; Limpanasithikul W; Jianmongkol S; Kerr SJ; Ruxrungtham K
    Expert Opin Drug Metab Toxicol; 2020 Jul; 16(7):551-564. PubMed ID: 32508203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low rates of nucleoside reverse transcriptase inhibitor and nonnucleoside reverse transcriptase inhibitor drug resistance in Botswana.
    Moyo S; Gaseitsiwe S; Zahralban-Steele M; Maruapula D; Nkhisang T; Mokaleng B; Mohammed T; Ditlhako TR; Bareng OT; Mokgethi TP; van Widenfelt E; Pretorius-Holme M; Mine MO; Raizes E; Yankinda EK; Wirth KE; Gaolathe T; Makhema JM; Lockman S; Essex M; Novitsky V
    AIDS; 2019 May; 33(6):1073-1082. PubMed ID: 30946161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Doravirine responses to HIV-1 viruses bearing mutations to NRTIs and NNRTIs under in vitro selective drug pressure.
    Brenner BG; Oliveira M; Ibanescu RI; Routy JP; Thomas R
    J Antimicrob Chemother; 2023 Aug; 78(8):1921-1928. PubMed ID: 37303226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efavirenz or nevirapine in three-drug combination therapy with two nucleoside-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals.
    Mbuagbaw LC; Irlam JH; Spaulding A; Rutherford GW; Siegfried N
    Cochrane Database Syst Rev; 2010 Dec; (12):CD004246. PubMed ID: 21154355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical relevance of the interaction when switching non-nucleoside reverse transcriptase inhibitors in patients infected with HIV.
    Dailly E; Allavena C; Deslandes G; Bouquie R; Jolliet P; Raffi F
    Curr Clin Pharmacol; 2014; 9(4):399-403. PubMed ID: 24218996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Looking for an active conformation of the future HIV type-1 non-nucleoside reverse transcriptase inhibitors.
    La Regina G; Coluccia A; Silvestri R
    Antivir Chem Chemother; 2010 Aug; 20(6):213-37. PubMed ID: 20710063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.